Open an account

ImageneBio

IMA · NASDAQ

$4.13+$0.13 (+3.25%)TodayMarket closed ·
Prev close $4.00

About IMA

ImageneBio, Inc. is a clinical-stage biotechnology company that boldly imagines a world where patients can be free from the burden of grievous immunological/autoimmune and inflammatory (I&I) diseases. The company is headquartered in San Diego, California and currently employs 15 full-time employees. The company went IPO on 2021-03-26. The firm is focused on developing disease-modifying treatments for immunological/autoimmune and inflammatory (I&I) diseases. The firm develops differentiated profiles that can effectively control and change the course of I&I diseases for affected patients, treat their symptoms, and improve quality of life. The Company’s lead asset is IMG-007, a novel non-depleting anti-OX40 mAb bioengineered with Fc N297A mutations to abolish antibody-dependent cellular cytotoxicity (ADCC). IMG-007 is designed to specifically bind to OX40 on activated T cells and block the interaction between OX40 and OX40L without killing the T cells. The firm is conducting a Phase 2b clinical trial of IMG-007 in patients with moderate-to-severe atopic dermatitis.

Employees
15
Headquarters
San Diego, California
Listed
Mar 26, 2021
Sector
Health Care
Industry
Pharmaceuticals
Website
inmagenebio.com

IMA key statistics

Market cap
46.88M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
12.54K
Volume
22.01K
Open price
$4.00
High today
$4.29
Low today
$3.98
52 Week high
$9.10
52 Week low
$3.90

ImageneBio (IMA) at a glance

ImageneBio (IMA) last traded at $4.13, with a market cap of 46.88M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $3.98 and $4.29. The current price is 3.8% above the day's low and 3.7% below its high.

Volume so far is 22.01K shares, above the average of 12.54K shares a day.

Over the past year ImageneBio has ranged from $3.90 to $9.10, and now sits 4% of the way up that range.

ImageneBio met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$0.63 per share against an estimate of -$0.904.

The average analyst price target is $18.36, 344.6% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

67%of 3 analyst ratings say Buy
  • Buy66.7%
  • Hold0.0%
  • Sell33.3%
Price target · 4 analystsAvg $18.36
Low
$2.02
Now
$4.13
High
$29.40

IMA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 21.5% on average.

  1. Q3 FY24: reported -$2.52 per share against an estimate of -$3.23
  2. Q4 FY24: reported -$2.28 per share against an estimate of -$2.30
  3. Q1 FY25: reported -$2.16 per share against an estimate of -$2.55
  4. Q2 FY25: reported -$0.72 per share against an estimate of -$1.70
  5. Q3 FY25: reported -$2.91 per share against an estimate of -$1.29
  6. Q4 FY25: reported -$1.42 per share against an estimate of -$1.46
  7. Q1 FY26: reported -$0.95 per share against an estimate of -$0.7105
  8. Q2 FY26: reported -$0.63 per share against an estimate of -$0.904

IMA news

  • Vandana Singh

    ImageneBio $30 Million Private Placement Ignites Stock

  • Market-Moving News for April 13th

  • 12 Health Care Stocks Moving In Tuesday's Pre-Market Session

  • 12 Health Care Stocks Moving In Monday's Pre-Market Session

  • Press releaseGlobe Newswire

    ImageneBio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update

Similar companies

Companies in the same industry as ImageneBio

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.